AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2023

May 4, 2023

31565_dirs_2023-05-04_35cb5060-a340-4f2c-9eb4-c53ac2b1b2c3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-05-02

Reporting Person: DArecca James (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-02	Common Stock	F	430	$81.66	Disposed	10246	Direct

Footnotes

F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2: This number includes unvested RSUs previously reported.